- Coordinator
- Universita Degli Studi Di Bari Aldo Moro, Italy
- Runs
- 1 September 2022 to 31 August 2026
- Status
- Running
- EU funding
- €6.2m
- Total cost
- €6.2m
- Partners
- 11 organisations in 6 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057430
What the project is doing
In the project's own words, from its summary on CORDIS.
Safe- and green-by-design are pre-market design approaches whereby the objectives of minimizing the use of hazardous chemicals, reducing greenhouse gas emissions, and fostering the reuse and recycling of materials in a circular economy are built into product design. SUSPHARMA fits the European need for sustainable development in modern industry and will develop during the action greener routes to prepare molecules, such as therapeutics and diagnostics.
The breakthrough innovation will involve:- use of renewable (bio-based) carbon for the building block of scaffolds and motifs for drug synthesis;- cleaner synthetic methodologies for C-X bond formation (that is, C-H functionalization to obtain C-C, C-F, and C-I bond formation);- development of new benchtop continuous purification methods, to remove impurity and recycle synthetic solvents;- integration of digitalization methods.- LCA and TEA assessment for sensibly reducing the impact of pharmaceutical production.
The project will thus benefit from an interdisciplinary domain, involving:- recent advances in biomass conversion for drug synthesis;- new developments in heterogeneous catalysis;- cutting-edge flow chemistry technologies (including synthesis and purification);- automation and machine learning. To address the challenge of green and digital transition and proper supply of health technologies and products, SUSPHARMA will focus on research and innovation activities that aim at integrating five breakthrough concepts: CAT-to-PHARMA, WASTE-to-PHARMA, FLOW-to-PHARMA, PUR-to-PHARMA, and DIGITAL to PHARMA.
This will deliver results that are directed to pharmaceutical industries, researchers, and innovators, prompting them to develop and produce greener pharmaceuticals that are either greener by design, intrinsically less harmful for the environment, or use greener and economically more sustainable manufacturing processes and technologies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Degli Studi Di Bari Aldo Moro | Bari | Italy | Coordinator |
| Vlaamse Instelling Voor Technologisch Onderzoek N.v. | Mol | Belgium | Participant |
| Universidad De Cordoba | Cordoba | Spain | Participant |
| Dompe Farmaceutici SpA | Milano | Italy | Participant |
| Politecnico Di Milano | Milano | Italy | Participant |
| C2cat BV | Ter Aar | Netherlands | Participant |
| Co2 Dry BV | Weesp | Netherlands | Participant |
| Feyecon Development & Implementation BV | Weesp | Netherlands | Participant |
| Universiteit Van Amsterdam | Amsterdam | Netherlands | Participant |
| Universidade De Aveiro | Aveiro | Portugal | Participant |
| Loughborough University | Loughborough | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI